Immunic, inc. to participate in investor conferences in january

New york, jan. 5, 2021 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced management's participation in the...
IMUX Ratings Summary
IMUX Quant Ranking